本文選題：非小細(xì)胞肺癌 + 腦轉(zhuǎn)移　； 參考：《皖南醫(yī)學(xué)院》2017年碩士論文

【摘要】：目的:研究分析EGFR基因突變與非小細(xì)胞肺癌腦轉(zhuǎn)移的相關(guān)性。方法:收集2013年12月至2016年08月于皖南醫(yī)學(xué)院弋磯山醫(yī)院病理科行EGFR基因檢測(cè)的非小細(xì)胞肺癌患者數(shù)據(jù)共389例,選取其中220例非小細(xì)胞肺癌患者為研究對(duì)象,回顧性分析EGFR基因突變類型、常見突變與非小細(xì)胞肺癌腦轉(zhuǎn)移的相關(guān)性,采用突變擴(kuò)增阻滯系統(tǒng)法(ARMS)對(duì)所有標(biāo)本進(jìn)行EGFR基因檢測(cè)。結(jié)果:389例非小細(xì)胞肺癌病人中,診斷為腦轉(zhuǎn)移的51例(13.11%),其中19號(hào)外顯子突變(23.65%)與21號(hào)外顯子突變(20.82%)最常見,占所有突變數(shù)的91.05%。入選的220例非小細(xì)胞肺癌患者中,腦轉(zhuǎn)移發(fā)生率為23.18%,EGFR基因突變好發(fā)于女性(p0.0001)、肺腺癌(p0.0001)病人,與病人的年齡(p=0.8933)、標(biāo)本來源(p=0.2755)無關(guān)。EGFR突變型病人腦轉(zhuǎn)移發(fā)生率與EGFR野生型病人腦轉(zhuǎn)移發(fā)生率無明顯統(tǒng)計(jì)學(xué)差異(p=0.6316),EGFR常見突變19del與L858R腦轉(zhuǎn)移的發(fā)生率也無明顯統(tǒng)計(jì)學(xué)差異(p=1.0000)。結(jié)論:非小細(xì)胞肺癌EGFR突變型病人腦轉(zhuǎn)移發(fā)生率與EGFR野生型病人腦轉(zhuǎn)移發(fā)生率無明顯相關(guān)性。非小細(xì)胞肺癌EGFR常見突變19del與L858R腦轉(zhuǎn)移的發(fā)生率無明顯相關(guān)性。NSCLC患者BM的發(fā)生率為23.18%(51/220)。
[Abstract]:Objective: to study the correlation between EGFR gene mutation and brain metastasis in non-small cell lung cancer. Methods: a total of 389 patients with non-small cell lung cancer (NSCLC) were collected from December 2013 to August 2016, and 220 patients with NSCLC were selected. The type of EGFR gene mutation and the correlation between the common mutation and brain metastasis of NSCLC were analyzed retrospectively. The EGFR gene was detected by mutation amplification block system. Results among 389 patients with non-small cell lung cancer, 51 cases with brain metastasis were diagnosed as brain metastases, among which exon 19 mutation was 23.65% and exon 21 mutation was 20.82%, accounting for 91.05% of all mutations. In 220 patients with non-small cell lung cancer, the incidence of brain metastasis was 23.18%. EGFR gene mutation was more common in female patients with p0.0001a and lung adenocarcinoma (p0.0001). There was no significant difference in the incidence of brain metastasis between the patients with EGFR wild type and the patients with EGFR wild type. There was no significant difference in the incidence of brain metastasis between 19del and L858R. There was no significant difference in the incidence of brain metastasis between 19del and L858R. Conclusion: there is no significant correlation between the incidence of brain metastasis in patients with EGFR mutation and the incidence of brain metastasis in EGFR wild-type patients. There was no significant correlation between EGFR mutation 19del and the incidence of L858R brain metastasis. The incidence of BM in patients with NSCLC was 23.18 / 221 / 220.
【學(xué)位授予單位】：皖南醫(yī)學(xué)院
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2017
【分類號(hào)】：R734.2

【參考文獻(xiàn)】

相關(guān)期刊論文 前4條

1 葛蒙晰;周鑫莉;詹瓊;黃若凡;梁曉華;;伴腦轉(zhuǎn)移的非小細(xì)胞肺癌EGFR突變率較高[J];中國(guó)腫瘤生物治療雜志;2016年03期

2 謝亞琳;梁繼珍;蘇寧;;吉非替尼與厄洛替尼在EGFR基因敏感突變晚期NSCLC患者一線治療中的療效比較[J];南方醫(yī)科大學(xué)學(xué)報(bào);2015年03期

3 林良安;劉志藝;楊建勝;賈向波;楊洋;姜格寧;;EGFR突變?cè)冖衿诜切〖?xì)胞肺癌患者中的分布趨勢(shì)[J];中華胸心血管外科雜志;2014年09期

4 姜斌,朱冠山,劉峰,龔圣濟(jì),姚寶娣,鐘鐳,朱忠政,曾驥孟;中國(guó)人非小細(xì)胞肺癌EGFR基因突變的研究[J];上海第二醫(yī)科大學(xué)學(xué)報(bào);2005年11期

，

本文編號(hào)：1864150